Blood Transfusion After Myocardial Infarction: Friend, Foe or Double-Edged Sword? by Papaioannou, Georgios I
Blood Transfusion After Myocardial 
Infarction: Friend, Foe or Double-Edged 
Sword? The CADILLAC study
Georgios I. Papaioannou, MD, MPH, FACC, FSCAI
A B S T R A C T
Combined mechanical and pharmacological interventions constitute the cornerstone 
of therapy for patients with ST-segment elevation acute myocardial infarction (AMI). 
These increasingly complex interventions offer morbidity and mortality advantage 
but are associated frequently with bleeding complications. Major bleeding is probably 
the most important non-cardiac complication in patients undergoing coronary artery 
intervention. Prior studies have identified anemia as a strong independent predictor 
of mortality and adverse cardiac events in this patient population. Limited data are 
available to guide transfusion decisions in patients with coronary artery disease and 
anemia either at baseline or after a complication of an angioplasty procedure.
The CADILLAC study sought to determine the relationship between red blood cell 
transfusion and clinical outcomes in patients undergoing primary percutaneous coro-
nary intervention for AMI. Out of 2,060 randomized patients, 82 (3.98%) received red 
blood cell transfusion during index hospitalization. Transfusion was independently as-
sociated with baseline anemia, older age, multivessel disease, and female gender. Pa-
tients transfused, versus patients not transfused, had significantly higher rates of one 
year mortality (23.9% vs. 3.4%), disabling stoke (2.5% vs. 0.5%), reinfarction (7.0% vs. 
2.2%) and composite major adverse cardiac events (41.0% vs.16.6%). After multivari-
able adjustment for potential confounders, red blood cell transfusion was indepen-
dently associated with mortality at 30 days and one year (hazard ratio 4.71 and 3.16 
respectively, both p=0.0005). The authors concluded that red blood cell transfusion 
after primary angioplasty in the setting of an AMI may be harmful or alternatively 
transfusion could be a marker of markedly increased risk, with further randomized 
studies needed to determine the optimal threshold for red blood cell transfusion in 
this patient population setting.
I N T R O D U C T I O N
Despite the widespread use of red blood cell (RBC) transfusions in patients with 
chronic anemia and active hemorrhage, there are limited data to guide transfusion 
decisions in patients with coronary artery disease (CAD). Additionally, improved 
survival in patients with CAD after RBC transfusion has not been demonstrated 
prospectively. Data from multiple series of patients with acute myocardial infarction 
(AMI) and transfusion varied possibly due to differences in the baseline hemoglobin 
levels as well as nadir hematocrit values after the procedure.1,2 In the large GUSTO 
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IIb trial (Global Use of Strategies To open Occluded coronary 
arteries) in which patients treated with only pharmacological 
reperfusion, blood transfusion was associated with a more than 
two fold increase in 30 day and one year mortality as well as 
increased rates of reinfarction.3 Similar results are available in 
patients undergoing percutaneous coronary intervention (PCI) 
and stable CAD disease, where blood transfusion was found 
an independent predictor of in-hospital and one year mortal-
ity.4 In a different setting, the landmark TRICC (Transfusion 
Requirement In Critical Care) randomized trial of critically 
ill patients found that a liberal transfusion strategy had no 
benefit, whereas a restrictive strategy of RBC transfusion 
was at list as effective and possibly a superior strategy in this 
population setting; however this could not be demonstrated 
for sure for patients with AMI or unstable angina.5
C A D I L L A C  T R I A L
In the CADILLAC (Controlled Abciximab and Device 
Investigation to Lower Late Angioplasty Complications) trial,6 
a total of 2,082 patients of any age with AMI within12 hours of 
symptom onset undergoing primary PCI in a native coronary 
artery eligible for stent implantation were randomized to one 
or four mechanical reperfusions strategies: coronary angi-
oplasty (PTCA) with or without abciximab versus PTCA and 
stenting with Multilink stent with or without abciximab. The 
design, principal results, major inclusion and exclusion criteria, 
as well as dosage protocols have been reported previously. The 
original study evaluated clinical outcomes including death 
from any cause, reinfarction, target vessel revascularization 
as a result of ischemia and disabling stroke during index hos-
pitalization, at 30 days and one year. In this particular study7 
evaluating the prognostic impact of RBC transfusion after pri-
mary angioplasty for AMI, patients were stratified into three 
groups: 1) patients administered one or more units of RBC due 
to moderate or severe bleeding; 2) patients administered RBC 
transfusion in the absence of overt major bleeding; 3) patients 
who did not receive RBC transfusion. Patients who underwent 
coronary artery bypass surgery during hospitalization were 
excluded from present analysis. With respect to the statistical 
analysis, categorical variables were compared using the Fisher 
exact test, continuous variables were presented as medians 
with interquartile ranges and were compared using the non-
parametric Kruskal-Wallis test. Clinical outcomes data were 
estimated by the Kaplan-Meier method and compared by log 
rank test. Multivariable analysis of predictors of mortality was 
performed using time-dependent Cox proportional hazards 
regression with stepwise selection using alpha entry and exit 
criteria of <0.10 and <0.15, respectively. A RBC transfusion 
was treated as a time-dependent covariate and entered the 
model along with all variables considered to be significant. 
To account for any confounding effect between transfusion 
and clinical outcomes a propensity score for RBC transfusion 
was constructed and included in the multivariable model; its 
discrimination was assessed by the goodness of fit with the 
Hosmer-Lemeshow statistic, and its predicted performance 
was assessed with the C statistic.
During the index hospitalization of 2,060 randomized 
patients not treated with bypass surgery, 82 patients (3.98%) 
received RBC transfusion, including 33 patients (1.60%) in 
whom a transfusion was administered in the setting of mod-
erate or severe bleeding and 49 patients (2.38%) who where 
transfused in the absence of moderate or severe bleeding. The 
RBC transfusions were administered to 75 out of 1,681 patients 
(4.5%) enrolled in the United States as compared with 7 out 
of 379 patient (1.8%) enrolled in other countries (p=0.015). 
One RBC unit was transfused in 8.5% of patients, two units 
in 54.9% patients and 3 units in 36.6% of patients.
Patients who received RBC transfusion were older, more 
frequently female, had a higher prevalence of prior gastrointes-
tinal bleeding, chronic renal insufficiency, multivessel disease 
and lower body mass index. Baseline values of hemoglobin 
and hematocrit were lower and as such anemia at baseline was 
more frequent in patients received RBC transfusions. Time 
from AMI onset to the first balloon inflation was also longer in 
patients who received RBC transfusions. With respect to pro-
cedural characteristics longer procedure duration, lower post 
procedure TIMI flow grade, smaller post procedure reference 
vessel diameter and lower rates of procedural success were also 
associated with subsequent RBC transfusion. Administration 
of abciximab per randomization did not differ significantly 
between the two groups; however more patients in a transfu-
sion group received abciximab for bailout indication.
Patients who received RBC transfusion associated with 
moderated or severe bleeding versus those without overt major 
bleeding versus those not transfused had significantly lower 
nadir hematocrit values. Patients receiving versus those not 
receiving RBC transfusion during index hospitalization had 
markedly higher rates of 30-day and one-year mortality, disa-
bling stroke, reinfarction and composite major adverse cardiac 
events. Additionally, patients who received blood transfusion 
without associated moderate or severe bleeding tended to 
have higher rates of 30 days and one-year death, target vessel 
revascularization and composite major adverse cardiac events 
than did patients who received transfusions in the setting of 
clinically evident hemorrhage. After multivariable adjustment 
for potential confounders transfusion propensity, RBC trans-
fusion was identified as an independent predictor of mortality 
at 30 days and one year.
D I S C U S S I O N
The principal findings of the CADILLAC analysis which 
was the first such investigation examining the relationship 
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between blood transfusion and outcomes in patients un-
dergoing primary PCI for AMI are the following: 1) RBC 
transfusion was administered to 3.9% of patients despite the 
absence of clinically overt moderate or severe bleeding in more 
than one half of these cases; 2) baseline anemia represented 
the strongest independent predictor of RBC transfusion; 3) 
patients received RBC transfusion had worse clinical and 
angiographic features at baseline, longer time from symptom 
onset to balloon inflation and PCI duration, worse procedural 
outcomes and larger infarct sizes; 4) after adjustment for 
potential confounders including baseline anemia and transfu-
sion propensity, RBC transfusion but not anemia remained 
a powerful independent predictor of 30-day and one-year 
mortality; 5) the prognosis following RBC transfusion tended 
to be worse among patients without an associate moderate or 
severe hemorrhagic event than in those who where transfused 
due to clinically evident major bleeding. The nadir hematocrit 
values that triggered blood transfusion in the present analysis 
varied greatly with more than one half of patients receiving 
a blood transfusion with a nadir hematocrit value of greater 
than 30%. These observations reflect the lack of a uniform 
standard to guide the appropriateness of blood product usage. 
Of the total 4% of patients who received transfusions roughly 
one in four died and in two suffered an adverse cardiac event 
at one year.8 This is after excluding all the patients who had 
coronary artery bypass surgery. However the incidence of 
anemia and its associated transfusion were so closely related 
that the resulting interaction interfered with identification of 
the real culprit, but the transfusion propensity score was the 
key element to clear these data analysis.
Some issues, however, needed to be commented. First, the 
study provides a post hoc analysis of prospectively collected 
data within the context of large randomized trial. Transfusion 
was a post randomization event and the association between 
transfusion and outcomes has the potential of risk of bias 
due to unmeasured residual confounders. Additionally, the 
anemia cause was never established and that may have major 
prognostic implications. Finally, the potential effect of discon-
tinuation of antithrombotic and antiplatelet medications due 
to bleeding was not investigated and may have contributed to 
a more adverse outcome.
In patients with AMI, bleeding prevention is of paramount 
importance. Multiple studies have shown that baseline anemia 
and transfusion where considered to be important predictors 
of adverse outcomes in patients artery doing PCI either in 
selective or emergency settings. Consequently, strategies that 
diminish bleeding risk while maintaining efficacy in reducing 
ischemic complications are very important. The role of newer 
anticoagulants, dose adjustments per gender, body mass index 
and baseline bleeding risk, meticulous puncture technique in 
the case of femoral approach or shifting to radial approach9 
are some important attractive measures to diminish bleeding 
risk. More important, once prevention have failed a threshold 
for optimal transfusion should be defined. Transfusion may 
simply be a predictor of an outcome, the proverbial friend of 
a friend. Accumulate evidence strongly suggest that in pa-
tients with AMI transfusion may indeed become a real “foe”. 
Therefore, until more information is available a conservative 
approach with restrictive indications of blood products trans-
fusion appears warranted. Widespread adoption of restrictive 
transfusion strategies might significantly improve clinical 
outcomes in this patient population, thus shifting this therapy 
into a trusting “friend”.
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